Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
about
Potential Gene Interactions in the Cell Cycles of Gametes, Zygotes, Embryonic Stem Cells and the Development of CancerTranscriptional network control of normal and leukaemic haematopoiesisCohesin mutations in myeloid malignancies: underlying mechanismsTranscription factor-mediated reprogramming toward hematopoietic stem cellsMAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.OncoCis: annotation of cis-regulatory mutations in cancer.Computational promoter modeling identifies the modes of transcriptional regulation in hematopoietic stem cellsExpression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulationIdentification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal.A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.Systematic analysis of hematopoietic gene expression profiles for prognostic prediction in acute myeloid leukemia.Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2aGenome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.A quantitative proteomics approach identifies ETV6 and IKZF1 as new regulators of an ERG-driven transcriptional network.Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis.A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.BloodChIP: a database of comparative genome-wide transcription factor binding profiles in human blood cells.Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.Molecular landscapes of human hematopoietic stem cells in health and leukemia.A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.The non-coding RNA landscape of human hematopoiesis and leukemia.Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.Selective dissociation between LSD1 and GFI1B by a LSD1 inhibitor NCD38 induces the activation of ERG super-enhancer in erythroleukemia cells.
P2860
Q26781101-54BABA87-AB8D-4A41-8589-BDFD7C3212F1Q27005940-729E6EA1-CED0-47D5-B12E-2E9729A62D8CQ27022740-70E0149A-02EB-47CA-AD01-7421AC3BB2FEQ27023005-322370E3-2D72-4675-B820-BA7310AFF1E4Q30277014-B939F3B7-41C4-46D0-9614-FC8EE5C7054BQ33759034-C998AB57-9B58-4ED5-8D6D-8DD3B0463571Q34474391-8704391D-7004-4338-AAB6-DBE4DEA84B75Q35142096-3A242959-5532-478F-A8B3-2BEC2509954AQ35550103-C42D54E2-64A5-47B9-8BB3-51D9787239DEQ35806108-506DBCBD-B76D-41CB-8C9C-3F06F19A479DQ36080675-8B02469F-E00D-4E43-8B41-2DCF972F170DQ36310257-D69B5AF1-3746-4EF9-BD87-DB77AD38E371Q36432056-F0D6769C-185C-466A-A577-06FF135F3188Q37226744-788F9A97-E972-4A9A-9147-7B02BC339B15Q37507603-45D7B381-7760-48AB-AB9B-898D47DFC4F8Q37575953-E1FF7481-918A-40A5-96A8-61519C074C97Q37645045-340EB0E8-E60D-45F1-BD20-BC88FD125FEEQ37661800-6EDA5210-BA55-4AF2-9D43-B836E0490580Q38253011-228FDDB5-1692-4AAC-B445-2FD460233E6DQ38265472-A0FBAA3F-D0AA-4AAC-B79E-699395BEAFF1Q38668304-8AF7C221-2F2F-4D28-875A-C91F24E55F92Q38695117-3BE39340-A49B-4A8E-B9B3-5A1EC4BC5E31Q38856290-E4A8F305-C932-4FD3-B1AB-C82CB263C8E7Q41331438-FC80B2B7-6138-47AD-917E-A90448D98560Q42183867-A733BFA6-0FC7-4EFD-9D12-D6BFA20CEA4EQ43070849-AFAE3D3B-4E95-49EA-8C97-D6E81B288FA4Q45847205-61B0D3C0-4AD2-4B7D-9FD2-AD09F0E141A6Q54348193-18C1BF5F-C7A3-4F73-A9A1-C5DD62C914C4
P2860
Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Activity of a heptad of transc ...... ome in acute myeloid leukemia.
@en
Activity of a heptad of transc ...... ome in acute myeloid leukemia.
@nl
type
label
Activity of a heptad of transc ...... ome in acute myeloid leukemia.
@en
Activity of a heptad of transc ...... ome in acute myeloid leukemia.
@nl
prefLabel
Activity of a heptad of transc ...... ome in acute myeloid leukemia.
@en
Activity of a heptad of transc ...... ome in acute myeloid leukemia.
@nl
P2093
P50
P1433
P1476
Activity of a heptad of transc ...... ome in acute myeloid leukemia.
@en
P2093
Alan Burnett
Christian Buske
Clare Pridans
Debbie Goode
Dominik Beck
Emma Gudgin
Eva Diffner
Jason W H Wong
John E Pimanda
Julie A I Thoms
P304
P356
10.1182/BLOOD-2012-07-446120
P407
P50
P577
2013-01-17T00:00:00Z